ERIN DOHERTY

Concepts (58)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Graft vs Host Disease
4
2023
543
1.040
Why?
Hematopoietic Stem Cell Transplantation
6
2023
1199
1.000
Why?
Leukemia, Megakaryoblastic, Acute
1
2019
20
0.630
Why?
Periosteum
1
2019
33
0.610
Why?
Killer Cells, Natural
1
2018
324
0.510
Why?
Bone Neoplasms
1
2019
430
0.460
Why?
Leukemia, Myeloid, Acute
1
2018
538
0.400
Why?
Transplantation Conditioning
4
2023
323
0.260
Why?
beta-Thalassemia
1
2023
28
0.220
Why?
Antibodies, Bispecific
1
2023
34
0.210
Why?
Cord Blood Stem Cell Transplantation
1
2023
47
0.210
Why?
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
2023
128
0.200
Why?
Burkitt Lymphoma
1
2023
146
0.200
Why?
Hematologic Diseases
1
2021
78
0.170
Why?
RNA, Viral
1
2022
539
0.160
Why?
Hodgkin Disease
1
2022
293
0.160
Why?
Acute Disease
1
2022
1101
0.160
Why?
Anemia, Sickle Cell
1
2021
340
0.140
Why?
Lower Extremity
1
2019
183
0.140
Why?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
2023
810
0.130
Why?
Child
7
2023
24516
0.120
Why?
Molecular Targeted Therapy
1
2017
353
0.120
Why?
Alemtuzumab
2
2023
88
0.100
Why?
Immunotherapy
1
2017
662
0.100
Why?
Neuroblastoma
1
2017
520
0.100
Why?
Humans
10
2023
124335
0.090
Why?
Child, Preschool
3
2023
14075
0.090
Why?
Retrospective Studies
5
2023
16225
0.070
Why?
Neoplasms
1
2021
2794
0.070
Why?
Neoplasm Recurrence, Local
2
2022
1127
0.050
Why?
Busulfan
1
2023
44
0.050
Why?
Immunoglobulins, Intravenous
1
2023
142
0.050
Why?
Texas
2
2021
3590
0.050
Why?
Carmustine
1
2022
26
0.050
Why?
Melphalan
1
2022
49
0.050
Why?
Transplantation, Homologous
1
2023
662
0.050
Why?
Cytarabine
1
2022
98
0.050
Why?
Transplantation, Autologous
1
2022
298
0.050
Why?
Unrelated Donors
1
2021
82
0.050
Why?
Rituximab
1
2022
156
0.050
Why?
Cyclophosphamide
1
2023
421
0.050
Why?
Recurrence
1
2023
1425
0.040
Why?
Hospitals
1
2021
396
0.040
Why?
Infant
2
2023
12475
0.040
Why?
Antineoplastic Combined Chemotherapy Protocols
1
2022
1240
0.030
Why?
Adolescent
2
2023
19355
0.030
Why?
Aged
2
2022
19461
0.030
Why?
Pandemics
1
2021
1102
0.030
Why?
Combined Modality Therapy
1
2017
1245
0.030
Why?
Female
1
2019
66271
0.030
Why?
Prospective Studies
1
2023
6083
0.020
Why?
Survival Rate
1
2017
2020
0.020
Why?
Young Adult
1
2022
8979
0.020
Why?
Risk Assessment
1
2017
3372
0.020
Why?
Middle Aged
1
2022
26443
0.010
Why?
Adult
1
2022
29376
0.010
Why?
Treatment Outcome
1
2017
12279
0.010
Why?
Male
1
2021
60990
0.010
Why?
DOHERTY's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (58)
Explore
_
Co-Authors (34)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_